|
[1]
|
Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment[J]. Neuroendocrinology, 2004, 80(Suppll):51-56. |
|
[2]
|
Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules[J]. Chest, 2000, 117(12):1232-1238. |
|
[3]
|
Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for seintigraphic and radiotherapeutic use[J]. Eur J Nucl Med, 2000, 27(2):273-282. |
|
[4]
|
McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives[J]. Q J Nuel Med,2000, 44(1):88-95. |
|
[5]
|
Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropanereatic malignancies[J].Semin Nuel Med, 2002, 32(1):123-132. |
|
[6]
|
Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with[In-DTPA]octreotide:the Rotterdam experience[J]. Semin Nucl Med, 2002, 32(1):110-122. |
|
[7]
|
Chinol M, Bodei L, Cremonesi M, et al. Receptormediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide:the experience of the European Institute of Oncology Group[J]. Semin Nucl Med, 2002,32(2):141-147. |
|
[8]
|
Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phel-Tyr3-octreotide[J]. Eur J Nucl Med, 2001, 28(3):426-434. |
|
[9]
|
Paganelli G, Bodei L, Chinol M, et al. Receptor mediated radiotherapy with 90Y-DOTATOC:results of a phase Ⅰ study[J]. J Nucl Med,2001, 42(1):36P. |
|
[10]
|
Waldherr C, Pless M, Maecke HR, et al. The clinical value of 90Y-DOTA]-d-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:a clinical phase Ⅱ study[J]. Ann Oncol,2001, 12(6):941-945. |
|
[11]
|
Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(4):610-616. |
|
[12]
|
De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings[J].Semin Nucl Med, 2002, 32(1):133-140. |
|
[13]
|
Smith MC, Liu J, Chen T, et al. OctreoTher:ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy[J]. Digestion, 2000, 62(Suppl 1):69-72. |
|
[14]
|
Valkema R, Kvols L, Jamar F, et al. Phase 1 study of therapy with 90Y-SMT487(OctreoTher) in patients with somatostatin receptor-positive tumors[J]. J Nucl Med, 2002, 43(1):33P. |
|
[15]
|
Bushnell D, Menda Y, Madsen M, et al. Assessment ofhepatic toxicity from treatment with 90Y-SMT 487(OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases[J]. Cancer Biother Radiopharm, 2003, 18(4):581-588. |
|
[16]
|
Bodei L, Handkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas[J]. Cancer Biother Radiopharm, 2004, 19(1):65-71. |
|
[17]
|
Pless M, Waldherr C, Maecke H, et al. Targeted radiotherapy for small cell lung cancer using 90Y-DOTATOC, an Yttriumlabelled somatostatin analogue:a pilot trial[J]. Lung Cancer, 2004, 45(3):365-371. |
|
[18]
|
Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ:an extended pilot study[J]. Eur J Nucl Med Mol Imag, 2002, 29(2):486-493. |
|
[19]
|
Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide:results and implications of the MAURITIUS trial[J]. Semin Nucl Med, 2002, 32(1):148-155. |
|
[20]
|
Virgolini I, Traub T, Novotny C, et al. Experience with indium-111and yttrium-90-labeled somatostatin analogs[J]. Curr Pharm Des,2002, 8(12):1781-1807. |
|
[21]
|
de Jong M, Breeman WA, Bernard BF, et al.[177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy[J]. Int J Cancer, 2001, 92(4):628-633. |
|
[22]
|
Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment with[177LuDOTA0, Tyr3] octreotate in patients with neuroendocrine tumors:interim results[J]. EurJ Nucl Med, 2003, 30(Suppl 2):S231. |
|
[23]
|
Boerman OC, Oyen WJ, Corstens FH. Between the Scylla andCharybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28(10):1447-1449. |
|
[24]
|
Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15. |
|
[25]
|
Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies[J]. Semin Nucl Med, 2002, 32(1):97-109. |
|
[26]
|
Schmitt JS, Wild D, Ginj M, et al. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2,3 and 5 for radiotherapy[J]. J Labelled Cpd Radiopharm, 2001, 44(3):s697-s699. |
|
[27]
|
De Jong M, Bernard HF, Breeman WAP, et al. Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only[J]. J Nucl Med, 2002, 43(1):123P-124P. |
|
[28]
|
Verwijnen SM, Sillevis Smith PA, Hoeben RC et al. Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene[J]. Cancer Biother Radiopharm,2004, 19(1):111-120. |
|
[29]
|
Gugger M, Reubi JC. Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast[J]. Am J Pathol, 1999, 155(11):2067-2076. |
|
[30]
|
Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting[J]. Eur J Nucl Med Mol Imaging, 2002, 29(3):855-862. |
点击查看大图
下载: